secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001104659-25-027545
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma reports positive Phase 1 data for COVID-19 drug ratutrelvir; no ritonavir needed
--------------------------------------------------------------------------------

- Phase 1 data at 600 mg/day for 10 days show trough blood levels ~13x EC50 and >EC90 for 2 days post-treatment.
- Ratutrelvir suppressed 18 SARS-CoV-2 strains including nirmatrelvir-resistant and Omicron variants in lab tests.
- No requirement for ritonavir boosting due to favorable metabolism, potentially reducing drug-drug interaction risks.
- Excellent safety/tolerability in SAD and MAD studies at all doses tested; target Phase 2 dose defined.
- Company plans FDA interactions to initiate Phase 2; investor event March 31, 2025 at 10:00 AM ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925027545/0001104659-25-027545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465925027545/tm2510212d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-027545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer